Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Reimbursement Connection® Kepivance® (palifermin) Patient Assistance/Support Programs - Overview Overview Amgen™ Oncology Assistance Aranesp® (darbepoetin alfa) Neulasta® (pegfilgrastim)...
Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Reimbursement Connection® Kepivance® (palifermin) Coding and Claims - Forms and Documents Overview Amgen™ Oncology Assistance Aranesp® (darbepoetin alfa) Neulasta® (pegfilgrastim) NEUPOGEN&...
Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Reimbursement Connection® Kepivance® (palifermin) Overview Amgen™ Oncology Assistance Aranesp® (darbepoetin alfa) Neulasta® (pegfilgrastim) NEUPOGEN® (Filgrastim) EPOGEN® (Epoetin...
About Amgen Fact Sheet 01.30.08 page 1
About Amgen Fact Sheet 01.30.08 About Amgen Amgen discovers, develops and delivers innovative human therapeutics.
Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Medical Professionals Reimbursement Connection® Patient Assistance/Support Programs - Overview Overview Products Disease / Condition Info Clinical Trials Resources R&D Vision Reimbursement Connection® Amgen™...
Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Medical Professionals Reimbursement Connection® Coding and Claims - Forms and Documents Overview Products Disease / Condition Info Clinical Trials Resources R&D Vision Reimbursement Connection® Amgen™...
Amgen - Medical Professionals - Reimbursement About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Medical Professionals Reimbursement Connection® Kepivance®-br-(palifermin) Overview Products Disease / Condition Info Clinical Trials Resources R&D Vision Reimbursement Connection® Amgen™ Oncology...
Amgen - Investors - Fact Sheets About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Investors Fact Sheet Overview Stock Info Fact Sheet Events Calendar Presentations Investor eKit Annual & Financial Reports Pipeline Frequently Asked Questions Leadership Team Corporate Governance Investor Contacts 2006...
Manufacturing Fact Sheet - July 24, 2006 Quick Facts Locations Fremont and Thousand Oaks, California Boulder and Longmont, Colorado Juncos, Puerto Rico West Greenwich, Rhode Island Bothell, Washington County Cork, Ireland (planned) Staff Approximately 8,000 Key Functions – Process Development – Manufacturing (clinical, bulk, formulation, fill and finish; contract manufacturing) – Quality and Regulatory...
author: Sally Jacob, (805) 313-4114
subject: An overview of Manufacturing at Amgen.
Manufacturing Fact Sheet - July 24, 2006 page 2
author: Sally Jacob, (805) 313-4114
subject: An overview of Manufacturing at Amgen.
Manufacturing Fact Sheet - July 24, 2006 page 1
author: Sally Jacob, (805) 313-4114
subject: An overview of Manufacturing at Amgen.
Amgen Inc Fact Sheet - July 24, 2006 Last Updated July 24 006 | Page 1 F a ct S h eet About Amgen Amgen discovers, develops and delivers innovative human therapeutics.Kepivance ® (palifermin) is prescribed to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers who are undergoing high- dose chemotherapy, with or without radiation,...
author: Sally Jacob, (805) 313-4114
subject: Amgen Inc Fact Sheet
Amgen Inc Fact Sheet - July 24, 2006 page 4
author: Sally Jacob, (805) 313-4114
subject: Amgen Inc Fact Sheet
Amgen Inc Fact Sheet - July 24, 2006 page 3
author: Sally Jacob, (805) 313-4114
subject: Amgen Inc Fact Sheet
Amgen Amgen - Investors - Fact Sheets 1, 2005) Kepivance(TM) (palifermin) Receives Positive Regulatory Opinion for Approval in Europe (Jul.palifermin) is the first and only therapy approved by the Food and Drug Administration (FDA) to decrease the incidence and duration of severe oral...
Microsoft Word - 3Q05 Fact Sheet.doc (* K/ DOQI is a trademark of the National Kidney Foundation Inc.) Kepivance™ Launched in 2005, Kepivance™ (palifermin) is the first and only therapy approved by the Food and Drug Administration (FDA) to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high- dose chemotherapy, with or...
author: btipton
Microsoft Word - 3Q05 Fact Sheet.doc page 3
author: btipton
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Amgen - Media - Media Contacts Amgen Corporate Communications Mailstop 28-1-C One Amgen Center Drive Thousand Oaks, CA 91320-1799 Corporate Earnings/Financial/ Governance/ Litigation/ Mergers & Acquisitions David Polk +1 805-447-4613 dpolk@amgen.com Research & Development/ Manufacturing/ International Initiatives Mary Klem +1 805-447-6979 mklem@amgen.com Government Policy/ Reimbursement Kelley Davenport +1 202-585...
Microsoft Word - 3Q05 Fact Sheet.doc page 4
author: btipton
Dec-16.pmd January 15, 2005 December 2004 Monthly letter to Shareholders Dear Shareholders, This monthly letter reviews December 2004 and briefly the full year 2004.
author: Reijer Lenstra
duplicates:http://www.biopharmafund.nl/French/In_Wall/News/BPF-TONIC-SICAV%20Monthly%20LettersPDF/Dec_04.pdf http://www.biopharmafund.nl/English/In_Wall/News/BPF-TONIC-SICAV%20Monthly%20LettersPDF/Dec_04.pdf
Dec-16.pmd page 1
author: Reijer Lenstra
duplicates:http://www.biopharmafund.nl/French/In_Wall/News/BPF-TONIC-SICAV%20Monthly%20LettersPDF/Dec_04.pdf http://www.biopharmafund.nl/Dutch/In_Wall/News/BPF-TONIC-SICAV%20Monthly%20LettersPDF/Dec_04.pdf http://www.biopharmafund.nl/English/In_Wall/News/BPF-TONIC-SICAV%20Monthly%20LettersPDF/Dec_04.pdf
Dec-16.pmd January 15, 2005 December 2004 Monthly letter to Shareholders Dear Shareholders, This monthly letter reviews December 2004 and briefly the full year 2004.Kepivance, a specific growth factor, was the first drug approved to treat oral mucositis (painful lesions of the...
author: Reijer Lenstra
